OOIR: Observatory of International Research

Papers

(The TQCC of Hepatology Research is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach	108
Liver injury is associated with severe coronavirus disease 2019 (COVID‐19) infection: A systematic review and meta‐analysis of retrospective studies	99
Evidence‐based clinical practice guidelines for liver cirrhosis 2020	89
Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update	65
Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update	62
Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020	62
Longitudinal changes of liver function and hepatitis B reactivation in COVID‐19 patients with pre‐existing chronic hepatitis B virus infection	59
MAFLD: Renovation of clinical practice and disease awareness of fatty liver	54
Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis	48
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)	42
Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)	41
Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan	39
Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study	39
Modelling the economic and clinical burden of non‐alcoholic steatohepatitis in East Asia: Data from Hong Kong	37
Report of the 21st Nationwide Follow‐up Survey of Primary Liver Cancer in Japan (2010–2011)	36
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice	34
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study	32
Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma	32
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease	31
Hepatocellular carcinoma after Fontan surgery: A systematic review	31
Diagnostic accuracy of FibroScan‐AST score to identify non‐alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non‐alcoholic fatty liver disease: Comparison betw	31
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy	30
Attenuation imaging based on ultrasound technology for assessment of hepatic steatosis: A comparison with magnetic resonance imaging‐determined proton density fat fraction	29
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria	29
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis	28

Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis	28
Clinicopathological characteristics of combined hepatocellular cholangiocarcinoma from the viewpoint of patient prognosis after hepatic resection: High rate of early recurrence and its predictors	28
Clinical and anthropometric characteristics of non‐obese non‐alcoholic fatty liver disease subjects in Japan	28
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma	26
Association of coagulopathy with liver dysfunction in patients with COVID‐19	26
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis	25
Immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma: Relationship with histopathological and molecular classification	25
Exosome circCMTM3 promotes angiogenesis and tumorigenesis of hepatocellular carcinoma through miR‐3619‐5p/SOX9	24
Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis	23
Pathological characteristics of liver sinusoidal thrombosis in COVID‐19 patients: A series of 43 cases	23
Calf and arm circumference as simple markers for screening sarcopenia in patients with chronic liver disease	22
Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular‐targeted agent sequential therapy: A propensity score‐matche	22
Effect of pemafibrate on fatty acid levels and liver enzymes in non‐alcoholic fatty liver disease patients with dyslipidemia: A single‐arm, pilot study	22
Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen	22
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multic	21
Treatment of hepatocellular carcinoma during the COVID‐19 outbreak: The Working Group report of JAMTT‐HCC	21
JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis	21
Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma	20
Zinc deficiency predicts overt hepatic encephalopathy and mortality in liver cirrhosis patients with minimal hepatic encephalopathy	20
Usefulness of the Global Leadership Initiative on Malnutrition criteria to predict sarcopenia and mortality in patients with chronic liver disease	19
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis	19
Serum matrix metalloproteinase‐7 in biliary atresia: A Japanese multicenter study	19
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria	18
Easy albumin–bilirubin score as a new prognostic predictor in hepatocellular carcinoma	18
Prevalence and characteristics of portopulmonary hypertension in cirrhotic patients who underwent both hepatic vein and pulmonary artery catheterization	18
Myostatin as a fibroblast‐activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma	18
Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma	17
Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection	17
Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression	17
Hepatocellular carcinoma and other complications of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in Japan: A structured review of published works	17
Characterization of hepatitis B virus DNA integration patterns in intrahepatic cholangiocarcinoma	16
aMAP score prediction of hepatocellular carcinoma occurrence and incidence‐free rate after a sustained virologic response in chronic hepatitis C	16
Lean/normal‐weight metabolic dysfunction‐associated fatty liver disease is a risk factor for reflux esophagitis	16
Liver disease in pregnancy	15
Clinical outcomes of direct‐acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment	15
Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study	15
Dysregulation of sphingolipid metabolic enzymes leads to high levels of sphingosine‐1‐phosphate and ceramide in human hepatocellular carcinoma	15
Transarterial‐ chemoembolization remains an effective therapy for intermediate‐stage hepatocellular carcinoma with preserved liver function	15
Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era	14
Real‐world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus‐related decompensated cirrhosis	14
Association between the albumin–bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH): A data‐mining analysis	14
Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study	13
Impact of viral eradication by direct‐acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus‐related compensated cirrhosis patie	13
Non‐invasive diagnosis of non‐alcoholic steatohepatitis and advanced fibrosis in Japan: A targeted literature review	12
Two hepatectomy cases for initially unresectable hepatocellular carcinoma after achieving a radiological complete response to sequential therapy with lenvatinib and transcatheter arterial chemoemboliz	12
Non‐invasive fibrosis markers are associated with mortality risk in both general populations and non‐alcoholic fatty liver disease patients	12
Omics‐derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases	12
Novel strategies for the early diagnosis of hepatitis B virus reactivation	12
Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta‐analysis of propensity score studies	12
Prospective study for an independent predictor of prognosis in liver cirrhosis based on the new sarcopenia criteria produced by the Japan Society of Hepatology	12

Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study	12
A novel rapid immunoassay of serum type IV collagen 7S for the diagnosis of fibrosis stage of nonalcoholic fatty liver diseases	12
Time‐dependent changes in the seroprevalence of COVID‐19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID‐19	11
Proposal of Stroop test cut‐off values as screening for neuropsychological impairments in cirrhosis: A Japanese multicenter study	11
Effects of a low‐intensity resistance exercise program on serum miR‐630, miR‐5703, and Fractalkine/CX3CL1 expressions in subjects with No exercise habits: A preliminary study	11
Prognosis of intrahepatic cholangiocarcinoma stratified by albumin–bilirubin grade	11
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis	11
Assessing liver stiffness with conventional cut‐off values overestimates liver fibrosis staging in patients who received the Fontan procedure	11
Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma	11
Meta‐analysis of the effect of sodium–glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non‐alcoholic fatty liver disease	11
Management of portal hypertension based on portal hemodynamics	11
Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease	10
Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population	10
Diagnostic criteria for acute‐on‐chronic liver failure and related disease conditions in Japan	10
Clinical course of hepatitis C virus‐positive patients with decompensated liver cirrhosis in the era of direct‐acting antiviral treatment	10
The efficacy of rituximab treatment for antibody‐mediated rejection in liver transplantation: A retrospective Japanese nationwide study	10
NBAS disease: 14 new patients, a recurrent mutation, and genotype–phenotype correlation among 24 Chinese patients	10
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma	10
Metabolomic/lipidomic‐based analysis of plasma to diagnose hepatocellular ballooning in patients with non‐alcoholic fatty liver disease: A multicenter study	10
Identification of microRNA‐96‐5p as a postoperative, prognostic microRNA predictor in nonviral hepatocellular carcinoma	10
Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)	10
Construction of a 13‐microRNA‐based signature and prognostic nomogram for predicting overall survival in patients with hepatocellular carcinoma	9
Effects of pemafibrate on primary biliary cholangitis with dyslipidemia	9
Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core‐related antigen assay	9
Does immune checkpoint inhibitor exhibit limited efficacy against non‐viral hepatocellular carcinoma?: A review of clinical trials	9
Single nucleus transcriptomics data integration recapitulates the major cell types in human liver	9
Novel artificial intelligent/neural network system for staging of nonalcoholic steatohepatitis	9
Treatment outcomes of stereotactic body radiation therapy using a real‐time tumor‐tracking radiotherapy system for hepatocellular carcinomas	9
Clinical practice guidelines for autoimmune hepatitis	9
2‐Step PLT16‐AST44 method: Simplified liver fibrosis detection system in patients with non‐alcoholic fatty liver disease	9
Metabolic dysfunction‐associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle‐aged and older US population	9
Time‐course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis	9
Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis	8
High fatty liver index is an independent predictor of ischemic heart disease during a 10‐year period in a Japanese population	8
Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma	8
Real‐world hospital mortality of liver cirrhosis inpatients in Japan: a large‐scale cohort study using a medical claims database	8
Hepatic stellate cell as a Mac‐2‐binding protein‐producing cell in patients with liver fibrosis	8
Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study	8
Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute‐on‐chronic liver failure development and prognosis in patients with liver cirrhosis	8
Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct‐acting antiviral therapy and achieved sustained	8
Favorable outcomes of surgical resection for extrahepatic recurrent hepatocellular carcinoma	8
Comparison of embolic effect between water‐in‐oil emulsion and microspheres in transarterial embolization for rat hepatocellular carcinoma model	8
Screening for portopulmonary hypertension using computed tomography‐based measurements of the main pulmonary artery and ascending aorta diameters in patients with portal hypertension	8
Proposal for new sleep disorder criteria in patients with chronic liver disease: Influence of liver‐related complications	8
Chemical conversion of aged hepatocytes into bipotent liver progenitor cells	7
Case of hepatitis B virus reactivation after ibrutinib therapy in which the patient remained negative for hepatitis B surface antigens throughout the clinical course	7
Development and multicenter validation of FIB‐6: A novel, machine learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in patients with chronic hep	7
Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: A large‐scale multicenter retrospective study	7
Metabolic dysfunction‐associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients	7
Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib	7
Multicenter study on the consciousness‐regaining effect of a newly developed artificial liver support system in acute liver failure: An on‐line continuous hemodiafiltration system	7
Accuracy of carbohydrate‐deficient transferrin as a biomarker of chronic alcohol abuse during treatment for alcoholism	7
Prognosis of patients with liver cirrhosis: A multi‐center retrospective observational study	7
Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching	7
Angiopoietin‐like protein 4 deficiency augments liver fibrosis in liver diseases such as nonalcoholic steatohepatitis in mice through enhanced free cholesterol accumulation in hepatic stellate cells	7
The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis	7
Association between dietary patterns and prognosis of hepatocellular carcinoma in the Guangdong liver cancer cohort study	7
Hepatocellular adenoma, approximately half and predominantly inflammatory subtype, in 38 Japanese patients with several differences in age, gender, and clinical background factors from Western populat	7
Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection	7
Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow‐up results of phase IIa clinical study	7
Serum Gas6 and Axl as non‐invasive biomarkers of advanced histological stage in primary biliary cholangitis	7
Changes in disease characteristics of primary biliary cholangitis: An observational retrospective study from 1982 to 2016	7
Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus	7
Hypofractionated radiotherapy for hepatocellular carcinomas adjacent to the gastrointestinal tract	6
Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample	6
LncRNA FGD5‐AS1 enhances the proliferation and stemness of hepatocellular carcinoma cells through targeting miR‐223 and regulating the expression of ECT2 and FAT1	6
Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir	6
Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients	6
Time‐resolved 3D cine phase‐contrast magnetic resonance imaging (4D‐flow MRI) can quantitatively assess portosystemic shunt severity and confirm normalization of portal flow after embolization of larg	6
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real‐world data	6
The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis	6
Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug‐eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma	6
Outcome of patients with acute liver failure awaiting liver transplantation in Japan	6
Postoperative direct‐acting antiviral treatment after liver resection in patients with hepatitis C virus‐related hepatocellular carcinoma	6
Significant improvement in portal‐systemic liver failure symptoms and successful management of portal‐splenic venous hemodynamics by the combination of interventional radiology and pharmacotherapy	6
Donor‐dominant one‐way matching of human leukocyte antigen‐A/B/DR alleles predicts graft‐versus‐host disease following living donor liver transplantation	6
Pancreas stiffness in liver cirrhosis is an indicator of insulin secretion caused by portal hypertension and pancreatic congestion	6
Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long‐term effects from a prospective study	6
Geriatric nutritional risk index as an easy‐to‐use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab	6
Serum levels of immunoglobulin M‐free inhibitors of macrophage/CD5L as a predictive and early diagnostic marker for nonalcoholic steatohepatitis‐associated hepatocellular carcinoma	6